Clementia begins Phase II extension trial of palovarotene to treat FOP patients

Canada-based Clementia Pharmaceuticals has started a Phase II extension trial of palovarotene, an investigational retinoic acid receptor gamma agonist, to treat patients with fibrodysplasia ossificans progressiva (FOP), a rare and severely disabling …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news